The Group's strategy

About the company

PROMOMED is a leading innovative biopharmaceutical company

Thanks to this, PROMOMED implements the concept of a full production cycle, responds promptly to the current needs of the industry, and also implements the latest technologies to create innovative medicines.

60%

The products produced by the Company are included in the state list of vital and essential medicines (VED).

200+

Doctors and Candidates of Sciences

3000+

Employees in the group of companies

1st place

in Russia, according to the number of medical studies according to the DSM, IQVIA, and AOKI according to the GRLS in 2022-2025.

TOP 1

in Russia, in the budget segment of the relevant market according to IQVIA

TOP-1

in Russia, the relevant market for the treatment of obesity and diabetes according to IQVIA

Strategy

PROMOMED Strategy

The strategy focuses on the development of innovative drugs, the implementation of best practices for promotion and continuous improvement of operational efficiency.

240

billion rubles.

Potential sales volume by 2032

TOP 3

Innovative fast-growing biopharmaceutical companies in Russia

Height

shareholder value

The operating model

  • R&D is a Key business driver
  • Developed competencies at the cutting edge of Biotech and high technology chemistry
  • Artificial intelligence and deep digitalization of internal processes: implementation of predictive analytics tools, automation of operations
  • Full-cycle production facilities
  • Integrated planning and project management systems
  • Effective transfer of substances and drugs

Product portfolio

  • At least 30 innovative lps and more than 90 new molecules
  • The leader in drugs for the treatment of obesity and diabetes
  • A leader in innovative, targeted oncology
  • A leader in the treatment of autoimmune diseases
  • A leader in the fight against chronic pain
  • The leader in technologically complex dosage forms

Commercialization

  • Effective/ sustainable management of commercial and budget sales channels
  • The best practice in Russia for the withdrawal of new drugs
  • Exports based on the innovation portfolio, 15% of total sales
  • Development of new and innovative sales channels, including online ones

Tasks

Expanding the horizons of therapy through innovative drugs

The market volume and share of PROMOMED in the market of new drugs1, billion rubles.

Expanding the horizons of therapy through innovative drugs
  • Focus on the production of innovative biotechnological drugs
  • Creation of affordable high-technology therapy for the health protection system
  • Solving the problems of chronic diseases
  • Changing the prognosis of previously incurable diseases of full-cycle capacity

  • 1 - Source: Strategy Partners Report
Outpacing the market growth rate of the underlying portfolio

Dynamics of sales of drugs from the basic portfolio, billion rubles.

Outpacing the market growth rate of the underlying portfolio
  • Playing on your own field, ahead of market growth
  • Deepening penetration in socially significant therapeutic areas. Portfolio offers
  • Replacement of outgoing foreign manufacturers with self-developed drugs
  • Ensuring National drug safety. Synthesis of proprietary APIs
Maintaining high standards of operational efficiency

EBITDA margin, %

Maintaining high standards of operational efficiency
  • Scaling and adapting the operating model while expanding production
  • Acceleration of capacity development in the field of biotechnology and R&D
  • Deep digitalization of internal processes and the use of AI
  • Well-established S&OP process and project management